These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease. Desikan RS; McEvoy LK; Holland D; Thompson WK; Brewer JB; Aisen PS; Andreassen OA; Hyman BT; Sperling RA; Dale AM; AJNR Am J Neuroradiol; 2013 Mar; 34(3):505-10. PubMed ID: 22976236 [TBL] [Abstract][Full Text] [Related]
8. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890 [TBL] [Abstract][Full Text] [Related]
9. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990 [TBL] [Abstract][Full Text] [Related]
10. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
11. CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders. Mattsson N; Insel P; Nosheny R; Zetterberg H; Trojanowski JQ; Shaw LM; Tosun D; Weiner M; Transl Psychiatry; 2013 Aug; 3(8):e293. PubMed ID: 23962923 [TBL] [Abstract][Full Text] [Related]
12. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147 [TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Ossenkoppele R; Mattsson N; Teunissen CE; Barkhof F; Pijnenburg Y; Scheltens P; van der Flier WM; Rabinovici GD Neurobiol Aging; 2015 Aug; 36(8):2340-7. PubMed ID: 25990306 [TBL] [Abstract][Full Text] [Related]
14. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease. Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737 [TBL] [Abstract][Full Text] [Related]
15. Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. Almeida RP; Schultz SA; Austin BP; Boots EA; Dowling NM; Gleason CE; Bendlin BB; Sager MA; Hermann BP; Zetterberg H; Carlsson CM; Johnson SC; Asthana S; Okonkwo OC JAMA Neurol; 2015 Jun; 72(6):699-706. PubMed ID: 25893879 [TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
17. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease. Wang L; Benzinger TL; Hassenstab J; Blazey T; Owen C; Liu J; Fagan AM; Morris JC; Ances BM Neurology; 2015 Mar; 84(12):1254-60. PubMed ID: 25716355 [TBL] [Abstract][Full Text] [Related]
18. Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults. Kresge HA; Liu D; Gupta DK; Moore EE; Osborn KE; Acosta LMY; Bell SP; Pechman KR; Gifford KA; Mendes LA; Wang TJ; Blennow K; Zetterberg H; Hohman TJ; Jefferson AL J Alzheimers Dis; 2020; 74(3):965-974. PubMed ID: 32144980 [TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
20. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]